NVO.CI
Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B · BCBA:NVO.CI
9,485.00 ARS325.00 +3.55%
Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B (BCBA:NVO.CI) last traded at 9,485.00 ARS, up 3.55% on the day. Over the past year the stock is down 12.82%. Its 52-week range is 8,510.00 to 11,140.00. It is in the Health Technology sector (Pharmaceuticals: Major).
Key statistics
Open9,400.00
Day range9,400.00 – 9,485.00
52-week range8,510.00 – 11,140.00
Volume317
Average volume (10 days)354
Market cap (USD)175.64 B
P/E1.60
EPS (TTM) (USD)3.99
Dividend yield4.40%
Beta (1 year)0.1013
Revenue (TTM) (USD)50.21 B
Employees68.79 K
Performance
+3.72%1 week
+7.11%1 month
−12.82%3 months
−12.82%6 months
−12.82%Year to date
−12.82%1 year
Technical rating
Buy
Daily summary of 11 oscillators and 15 moving averages. See every indicator
Latest headlines
- Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up NextStocktwits · 02 Nov 2026
- Jobs, Midterm Elections, Apple, Palantir, McDonald's, Moderna, and More to Watch This Week — Barrons.comDow Jones Newswires · 01 Nov 2026
- Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growthSeeking Alpha · 31 Oct 2026
- Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on CancerBenzinga · 29 Oct 2026
- Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trialReuters · 28 Oct 2026
- Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible (UPDATED)Benzinga · 28 Oct 2026
- LLY Vs NVO: Lilly’s Retatrutide Beats Novo’s Ozempic In Head-To-Head Trial — Retatrutide More Than Doubles Weight LossStocktwits · 28 Oct 2026
- Lilly's next-gen drug outshines Ozempic on weight loss, blood sugar control in trialReuters · 28 Oct 2026
Market data from TradingView’s public feed, delayed as the exchange requires. For study only, not investment advice.